Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections
- 1 February 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 29 (2) , 188-192
- https://doi.org/10.1128/aac.29.2.188
Abstract
Serum, urine, tissue, and body fluids were collected from 40 adult patients who were receiving imipenem/cilastatin treatment for serious infections. Thirty-two patients were given 1 g every 6 h (4 g/day), and eight received 500 mg (2 g/day). Mean peak concentrations in serum were 34.9 +/- 4.0 micrograms/ml for the 1-g dose and 26.6 +/- 2.5 micrograms/ml for the 500-mg dose. Trough levels were 3.1 and 1.0 micrograms/ml, respectively. No evidence of drug accumulation was found after comparing peaks measured early in the treatment with those measured late. Peak levels were only marginally increased when infusions were given over 30 versus 60 min. The mean serum half-life was 82.0 +/- 25.3 min, with a range of 50 to 138 min. The apparent volume of distribution was 0.35 +/- 0.13 liter/kg, and the mean total body clearance was 0.183 +/- 0.067 liter/kg per h. Creatinine clearance correlated directly with the plasma elimination rate and inversely with the serum half-life. Moreover, total body clearance fell as the age of the patient rose. The mean urinary recovery was 39.1 +/- 12.8% (range, 15.0 to 59.2%) and did not correlate with creatinine clearance until it was below 15 ml/min. Of 20 specimens of various gastrointestinal secretions, 13 had imipenem concentrations that were low, but above the MIC for most resident flora. Pus, sputum, and bone all had concentrations of the drug sufficient to inhibit the infecting organisms, and these levels reflected generally excellent clinical responses.This publication has 14 references indexed in Scilit:
- Multiple-dose pharmacokinetics of imipenem-cilastatinAntimicrobial Agents and Chemotherapy, 1984
- A multiclinic randomized study of the comparative efficacy, safety and tolerance of imipenem/cilastatin and moxalactamEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984
- Impact of imipenem/cilastatin therapy on faecal floraEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984
- Imipenem versus moxalactam in the treatment of serious infectionsAntimicrobial Agents and Chemotherapy, 1983
- Effect of cefoperazone on faecal floraJournal of Antimicrobial Chemotherapy, 1983
- A program for non-linear regression analysis to be used on desk-top computersComputer Programs in Biomedicine, 1980
- In vitro activity of N-formimidoyl thienamycin (MK0787)Antimicrobial Agents and Chemotherapy, 1980
- MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activitiesAntimicrobial Agents and Chemotherapy, 1980
- Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibioticsAntimicrobial Agents and Chemotherapy, 1980
- Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patientsJournal of Pharmacokinetics and Biopharmaceutics, 1976